Drug profile · INN
ritonavir
NORVIR
ritonavir (NORVIR) is a cytochrome p450 3a inhibitor. Associated with AbbVie. Route of administration: oral. Current US regulatory status: approved.
Drug details — ritonavir
- US status
- approved
- Class
- Antiinfectives for systemic use (J05)
- Route
- ORAL
- Patents
- 1
- Programs
- 10
- Data quality
- 0.89
Quick answer
ritonavir (NORVIR) is a cytochrome p450 3a inhibitor. Associated with AbbVie. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Cytochrome P450 3A inhibitor
Primary target: Cytochrome P450 3A
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is ritonavir?
ritonavir (NORVIR) is a cytochrome p450 3a inhibitor. Associated with AbbVie. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for ritonavir?
NORVIR is a marketed brand name for ritonavir. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ritonavir?
ritonavir has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.